Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 1 1

Status

Completed 2Withdrawn 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other solid neoplasm 3

Conditions

Carcinoma, Hepatocellular 131Liver Neoplasms 42Carcinoma, Renal Cell 36Leukemia, Myeloid, Acute 32Neoplasm Metastasis 26Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 22Kidney Neoplasms 16Neoplasms 14Prostatic Neoplasms 12Pancreatic Neoplasms 12Recurrence 11Lung Neoplasms 11Colorectal Neoplasms 10Sarcoma 9Melanoma 9Brain Neoplasms 9Myelodysplastic Syndromes 8Glioblastoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Leukemia 6Urinary Bladder Neoplasms 5Thyroid Neoplasms 5Rectal Neoplasms 5Multiple Myeloma 5Leukemia, Myelomonocytic, Chronic 5Stomach Neoplasms 4Ovarian Neoplasms 4Liver Diseases 4Gliosarcoma 4

Interventions

Sorafenib 3pazopanib 2Sunitinib 2eribulin 1Temozolomide 1Sirolimus 1Irinotecan 1Erlotinib Hydrochloride 1Arsenic Trioxide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Refractory Solid Tumors × Sorafenib × Clear all
NCT02691780 2019-12-30

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Samsung Medical Center

Phase NA Withdrawn
Other solid neoplasm

Refractory Solid Tumors

NCT02450149 2017-03-13

Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors

Samsung Medical Center

Phase NA Completed
1 enrolled
Other solid neoplasm

Refractory Solid Tumors

NCT00759928 2014-07-02

PK Trial of Sorafenib & Erlotinib in Patients With Refractory Solid Tumors

SCRI Development Innovations, LLC

Phase 1 Completed
48 enrolled
Other solid neoplasm

Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡